Harrow and iOR Partners Expand National Product Supply Agreement
November 30 2022 - 8:00AM
Business Wire
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company
exclusively focused on the discovery, development, and
commercialization of innovative ophthalmic prescription therapies,
and iOR Partners, the pioneer in office-based surgery in the field
of ophthalmology, today jointly announced the expansion of their
national product supply agreement to provide Harrow’s entire
formulary compounded ophthalmic products to iOR Partners’ expanding
office-based surgery locations across the United States.
“We are thrilled to be working alongside iOR Partners as they
mobilize an increasing number of cataract surgeons to perform
surgery in an office-based environment, offering more personalized
care in a patient-friendly setting,” said Mark L. Baum, Chairman
and CEO of Harrow. “iOR Partners assists practices nationwide to
make office-based ophthalmic surgery a reality. Our mission has
always focused on making medications accessible and affordable, and
working with iOR Partners, the national leader in this fast-growing
area of ophthalmic surgery, represents an important and growing
channel for Harrow to meet our mission.”
“Harrow, through its ImprimisRx division, is the gold standard
in supplying innovative compounded ophthalmic formulations that
meet the highest federal manufacturing standards. Their commitment
to quality, exceptional customer service, and the breadth of their
portfolio are why we chose them as our partner,” said Tony Burns,
Founder and Principal of iOR Partners. “These qualities support our
confidence that we are delivering on our promise of personalized
care that’s safe and comfortable for patients.”
Burns continued, “One excellent example of a product we find
compelling is the MKO Melt®, which has allowed us to substantially
reduce the use of opioids and needles during office-based surgical
procedures. As we continue to grow and assist cataract surgeons
with their vision of providing office‑based cataract surgery, we
look forward to collaborating to further expand our services.”
About iOR Partners
iOR Partners, LLC is paving the way for the future of cataract
surgery with innovative, office-based surgery suites. iOR surgical
suites provide cataract surgeons the ability to offer more
personalized care in a safe and comfortable surgical environment.
The company’s turnkey solution includes assistance with space
build-out, acquiring surgical equipment, staff training, insurance
acquisition, accreditation, and compliance services. iOR Partners
is the only company dedicated to ophthalmic office-based surgery
and partners with practices nationwide. For more information, visit
iorpartners.com.
About Harrow
Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company
exclusively focused on the discovery, development, and
commercialization of innovative ophthalmic prescription therapies
for the U.S. market that are accessible and affordable. For more
information about Harrow, please visit the Investors section of the
corporate website, harrow.com.
Harrow Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include the continued impact of the COVID-19 pandemic and
any future health epidemics on our financial condition, liquidity
and results of operations; our ability to make commercially
available our FDA-approved products and compounded formulations and
technologies in a timely manner or at all; market acceptance of the
Company’s products and challenges related to the marketing of the
Company’s products; risks related to our pharmacy operations; our
ability to enter into other strategic alliances, including
arrangements with pharmacies, physicians and healthcare
organizations for the development and distribution of our products;
our ability to obtain intellectual property protection for our
assets; our ability to accurately estimate our expenses and cash
burn, and raise additional funds when necessary; risks related to
research and development activities; the projected size of the
potential market for our technologies and products; unexpected new
data, safety and technical issues; regulatory and market
developments impacting compounding pharmacies, outsourcing
facilities and the pharmaceutical industry; competition; and market
conditions. These and additional risks and uncertainties are more
fully described in Harrow’s filings with the Securities and
Exchange Commission, including its Annual Report on Form 10‑K and
its Quarterly Reports on Form 10-Q. Such documents may be read free
of charge on the SEC's website at www.sec.gov. Undue reliance
should not be placed on forward-looking statements, which speak
only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward‑looking
statements to reflect new information, events, or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
* Harrow’s compounded formulations are customized to meet unique
patient and practitioner needs. No compounded medication is
reviewed by the FDA for safety or efficacy. Harrow does not
compound copies of commercially available products.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221130005317/en/
For Harrow: Investors: Jamie Webb Director of
Communications and Investor Relations jwebb@harrowinc.com
615-733-4737
Media: Deb Holliday Holliday Communications, Inc.
deb@hollidaycommunications.net 412-877-4519
For iOR Partners: Media: Brooke Basaldua
bbasaldua@iorpartners.com 816-897-7670
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2023 to Apr 2024